# CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Source: https://onco.cc/trials/nct04637763/  
OnCo record `nct04637763` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Vispacabtagene regedleucel run by Caribou Biosciences, Inc., active and no longer recruiting.

## Summary

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) is a phase 1 interventional study registered as NCT04637763 by Caribou Biosciences, Inc., with 72 participants planned, started 2021-05-26. Conditions recorded: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma and B Cell Non-Hodgkin's Lymphoma. Interventions recorded: CB-010, Cyclophosphamide and Fludarabine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04637763
- Phase: 1
- Setting: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
- Sponsor: Caribou Biosciences, Inc.
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT04637763: https://clinicaltrials.gov/study/NCT04637763

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Vispacabtagene regedleucel](https://onco.cc/drugs/vispacabtagene-regedleucel/)
- companies: [Caribou Biosciences](https://onco.cc/companies/caribou/)

---
JSON: https://onco.cc/api/v1/entities/nct04637763.json